To further investigate the potential benefit of inhibiting ChREBP activity during HCC development, we took advantage of the small-molecule SBI-993, recently identified as a potent inhibitor of ChREBP activity33. This evidence concerns the gene MLXIPL and hepatocellular carcinoma.